Stock Watch: 2022 Starts Badly For Biotech
The Usual Early-Year Flurry Of Good News Is Absent
A slow start to the year in health care is usually tempered by announcements that build up to investor conference season. However, early 2022’s plethora of negative announcements may continue biotech’s unloved status of 2021.
